Results have been released from the clinical trial in Buffalo, NY.
This study included 500 participants who were diagnosed with various neurological diseases including MS and as well as additional healthy persons. The reason was to determine the correlation between MS and CCSVI.
Their findings have shown that more then 55% of MS patients who participated in the initial study were found to have the venous abnormality that Dr Zamboni termed CCSVI, with an additional 10% who were borderline. This compares to a near 26% of patients without MS who were also found to have the condition.
The results have encouraged Dr Robert Zivandinov whos is “cautiously optimistic and excited”. As such Dr Zivandinov and his team at the Buffalo Neuroimaging Analysis Center (BNAC) to continue this study into a second phase. This new study will use more advanced diagnostic tool an will examine an additional 500 patients.
Complete data from the study will be presented in April and the American Academy of Neurology meeting in April.
